Canada approves AstraZeneca's COVID-19 shot in boost to vaccination push

Canada approves AstraZeneca's COVID-19 shot in boost to vaccination push

Independent advisers to the FDA began daylong discussions on whether to allow widespread use of Johnson & Johnson's vaccine, setting the stage for a final decision within days.

More than 47 million people in the USA, or 14 per cent of the population, have received at least one shot of the two-dose vaccines from Pfizer and Moderna, which FDA authorized in December.

The Alberta government has already announced who will be included in phases one and two of its vaccine, including health-care workers, seniors 75 years of age and older, as well as people living in various congregate settings. "So these are the vaccines that we need if we want to be having all the pharmacies vaccinating, all the family doctors' offices vaccinating, it's much, much easier to work with these".

Janssen's vaccine is different from the Pfizer and Moderna vaccines, which are made using a new technology that employs genetic material called messenger RNA or mRNA.

If many Americans opted to wait for a preferred vaccine, it would not only leave more people at risk of developing a serious case of covid, but would also likely slow down the country's vaccination program, which only recently started gaining steam after a tepid start. After adding in moderate cases, the total effectiveness dropped to about 66 per cent.

"In terms of selecting from the range of options, I don't believe that's part of the plan at this point", Premier John Horgan told reporters Friday when asked if people may be able to pick which of the three approved vaccines they wish to receive. That wasn't the case last fall, when Pfizer and Moderna were wrapping up testing, and it's not clear if their numbers would hold against the most worrisome of those variants.

"It has been offered not only to the diplomats of countries but also to those of United Nations agencies and intergovernmental organizations working in India".

Health Canada approves third COVID-19 vaccine

"Although cases, hospitalizations and deaths are coming down, there's still a lot of community transmission in this country", Moss said.

"We may be done with the virus, but clearly the virus is not done with us", Centers for Disease Control and Prevention director Dr. Rochelle Walensky, said, speaking at the White House on Friday.

New Jersey could get an initial shipment of about 70,000 doses of Johnson & Johnson's new one-dose vaccine for the coronavirus next week and the same amount in subsequent weeks if federal health officials give the vaccine approval as expected, Gov.

Johnson & Johnson said the company is ready to provide approximately 20 million shots by the end of March, along with an additional 100 million doses over the summer.

While it may prove surmountable in the end, health policymakers will still have to grapple with the question of which vaccines to deploy, and in what order, ahead of potential repeat inoculations.

At Yale, Balcezak is struggling with how to make the best use of the J&J shot's advantages without appearing to target it to underserved populations.

The tough storage and distribution requirements put Pfizer and Moderna at a disadvantage against other COVID-19 vaccine makers. "We are very, very confident in our ability to meet targets", says Alcorn. "We need to get them protected".

Related Articles